Quantum BioPharma Featured in CTV W5 Investigation on Stock Manipulation Allegations

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that CTV News' flagship investigative program W5 is airing a three-part series examining the company and its allegations of stock market manipulation. The series, which began airing today, focuses on what the company describes as illegal trading tactics that nearly derailed its multiple sclerosis research program.

W5 investigative reporter Jon Woodward introduces Part One in an article titled "Was a Canadian company's multiple sclerosis research nearly derailed by 'market manipulation'?" The investigation highlights "stock spoofing," an illegal trading tactic that forms the central basis of Quantum BioPharma's USD $700 million lawsuit against CIBC and RBC. Stock spoofing involves placing fake orders to create artificial market activity and manipulate stock prices.

Quantum BioPharma CEO Zeeshan Saeed expressed gratitude for W5's reporting and reiterated the company's primary goal of advancing Lucid-MS, a drug candidate that has shown potential in animal studies to halt and reverse nerve-cell degradation in multiple sclerosis. The company maintains that the alleged market manipulation activities threatened to undermine its research and development efforts for this promising treatment.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of its lead compound, Lucid-MS, which represents a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.

The company also maintains strategic business interests through its ownership stake in Unbuzzd Wellness Inc., where Quantum BioPharma retains 20.11% ownership as of March 31, 2025, along with royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Additional strategic investments are managed through the company's wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

The W5 investigation and the ongoing $700 million lawsuit against major Canadian financial institutions highlight the complex challenges facing emerging biopharmaceutical companies in navigating capital markets while advancing critical medical research. The outcome of these legal proceedings could have significant implications for how market manipulation is addressed in the pharmaceutical and biotechnology sectors, potentially affecting investor confidence and regulatory oversight in publicly traded healthcare companies.

For investors seeking additional information about Quantum BioPharma, the company maintains a newsroom available at https://ibn.fm/QNTM where updates and corporate announcements are regularly posted. The broader implications of this case extend beyond Quantum BioPharma specifically, touching on issues of market integrity, investor protection, and the delicate balance between financial market operations and medical innovation funding.